Iterum Therapeutics (ITRM) Competitors $0.98 +0.00 (+0.31%) As of 12:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. BIOA, MOLN, ALEC, VTYX, LXEO, THTX, BDTX, ALTS, LYEL, and IKTShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include BioAge Labs (BIOA), Molecular Partners (MOLN), Alector (ALEC), Ventyx Biosciences (VTYX), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), Black Diamond Therapeutics (BDTX), ALT5 Sigma (ALTS), Lyell Immunopharma (LYEL), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. Its Competitors BioAge Labs Molecular Partners Alector Ventyx Biosciences Lexeo Therapeutics Theratechnologies Black Diamond Therapeutics ALT5 Sigma Lyell Immunopharma Inhibikase Therapeutics BioAge Labs (NASDAQ:BIOA) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends. Is BIOA or ITRM more profitable? Company Net Margins Return on Equity Return on Assets BioAge LabsN/A N/A N/A Iterum Therapeutics N/A N/A -71.37% Do institutionals and insiders have more ownership in BIOA or ITRM? 9.2% of Iterum Therapeutics shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by insiders. Comparatively, 9.2% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend BIOA or ITRM? Iterum Therapeutics has a consensus price target of $9.00, indicating a potential upside of 815.56%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Iterum Therapeutics is more favorable than BioAge Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAge Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, BIOA or ITRM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAge LabsN/AN/A-$71.11MN/AN/AIterum TherapeuticsN/AN/A-$24.77M-$0.99-0.99 Does the media prefer BIOA or ITRM? In the previous week, BioAge Labs and BioAge Labs both had 1 articles in the media. Iterum Therapeutics' average media sentiment score of 1.89 beat BioAge Labs' score of 0.93 indicating that Iterum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment BioAge Labs Positive Iterum Therapeutics Very Positive SummaryIterum Therapeutics beats BioAge Labs on 6 of the 8 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.32M$2.43B$5.56B$9.26BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-0.999.1428.5819.56Price / SalesN/A711.83434.47183.65Price / CashN/A164.3436.0257.93Price / Book-6.554.658.165.58Net Income-$24.77M$30.99M$3.24B$257.82M7 Day Performance-7.26%-0.08%-0.64%-0.39%1 Month Performance-1.70%7.08%4.93%7.80%1 Year Performance-26.91%-6.56%26.04%12.95% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics2.0615 of 5 stars$0.98+0.3%$9.00+815.6%-38.0%$39.32MN/A-0.9910Positive NewsBIOABioAge LabsN/A$4.18-2.3%N/AN/A$153.44MN/A0.00N/AMOLNMolecular Partners3.0736 of 5 stars$3.61-4.0%$12.00+232.4%-43.5%$151.81M$2.23M-1.88180Positive NewsGap DownALECAlector3.8285 of 5 stars$1.44-4.6%$4.00+177.8%-72.9%$150.99M$100.56M-1.14270Gap UpVTYXVentyx Biosciences3.4706 of 5 stars$2.04-1.9%$10.00+390.2%+6.7%$148.01MN/A-1.1730Positive NewsLXEOLexeo Therapeutics2.0196 of 5 stars$4.54+2.0%$16.60+265.6%-68.3%$147.73M$650K-1.3858Gap UpHigh Trading VolumeTHTXTheratechnologiesN/A$3.17-0.9%N/A+103.9%$147.14M$85.87M-39.63140Earnings ReportHigh Trading VolumeBDTXBlack Diamond Therapeutics2.8619 of 5 stars$2.50-3.1%$12.80+412.0%-51.0%$146.71MN/A41.6790News CoveragePositive NewsALTSALT5 Sigma0.1337 of 5 stars$7.54-8.4%N/AN/A$143.65M$12.53M0.00170LYELLyell Immunopharma3.2463 of 5 stars$9.15-5.6%$15.00+63.9%-73.5%$143.49M$60K-0.37270News CoverageIKTInhibikase Therapeutics1.4904 of 5 stars$1.93+2.1%$6.50+236.8%+20.8%$143.48MN/A-0.726 Related Companies and Tools Related Companies BioAge Labs Alternatives Molecular Partners Alternatives Alector Alternatives Ventyx Biosciences Alternatives Lexeo Therapeutics Alternatives Theratechnologies Alternatives Black Diamond Therapeutics Alternatives ALT5 Sigma Alternatives Lyell Immunopharma Alternatives Inhibikase Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITRM Stock Alerts